Antimicrobial properties of heterocyclic compounds against clinical mastitis isolates

• Autor(a) principal: Acosta,Atzel C.
• Data de Publicação: 2021
• Outros Autores: Cardoso,Marcos V.O., Oliveira Filho,Gevanio B., Pinheiro Junior,José W., Leite,Ana Cristina L., Mota,Rinaldo A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Pesquisa Veterinária Brasileira (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-736X2021000100240
• topic: Heterocyclic compounds; clinical mastitis; thiazole derivatives; thiazolidinone derivatives; biological activity; antibacterial activity; MIC; MBC

ABSTRACT: Mastitis causes significant economic losses to the dairy cattle industry. The present study aimed to evaluate the antibacterial properties of 39 heterocyclic derivatives (1,3-thiazoles and 4-thiazolidinones) against clinical mastitis isolates from dairy cows. Milk samples were collected from cows with clinical mastitis and the bacterial species were identified by PCR. Antibacterial activity was assessed using the broth microdilution method. First, 39 heterocyclic compounds were tested against four bacterial isolates (Staphylococcus aureus, Streptococcus agalactiae, Corynebacterium bovis and Escherichia coli) randomly chosen from those recovered from the milk samples (Study 1). Subsequently, the compounds with the strongest antibacterial activity were tested against all the bacterial isolates recovered from the milk samples (Study 2). 1,3-thiazoles showed the strongest antibacterial activity, specially compounds 30 and 38, which also showed bactericidal properties according to their minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values. Corynebacterium spp. and Enterobacteriaceae isolates were the most susceptible to compounds 30 and 38. Compounds 30 and 38 are promising targets for new antimicrobial agents.